Cancer Family
Reproductive System Neoplasm
CI-CAN-00000338Explore in graph →
Non-malignant3,041 active trials38 approved drugs197 evidence items
- NCIt
- C3674
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000338Explore in graph →
Clinical trials
13,668 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02059265 | Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer | terminated | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Aug 1, 2023 | clinicaltrials |
| NCT04424641 | A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 48 | GenmabINDUSTRY | 4 | Jul 25, 2023 | clinicaltrials |
| NCT00788125 | Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | City of Hope Medical CenterOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT02640534 | Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone | terminated | Phase 2 | 169 | Swiss Cancer InstituteOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT01133756 | E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125 | terminated | Phase 1 / Phase 2 | 7 | Eisai Inc.INDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT01326312 | Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer(GTx758) | terminated | Phase 2 | 159 | GTxINDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03824704 | A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) | terminated | Phase 2 | 1 | pharmaand GmbHINDUSTRY | 1 | Jun 12, 2023 | clinicaltrials |
| NCT02516670 | Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer | terminated | Phase 2 | 50 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 7, 2023 | clinicaltrials |
| NCT04843319 | To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer(VERU-100) | terminated | Phase 1 / Phase 2 | 24 | Veru Inc.INDUSTRY | 1 | May 19, 2023 | clinicaltrials |
| NCT03642990 | NR in Chemo-induced Peripheral Neuropathy | terminated | Phase 2 | 5 | Donna Hammond, PhDOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT04085991 | Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer(CROSSBOW) | terminated | Phase 2 | 11 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT04423913 | Safety, Tolerability, Distribution & Dose Effect of Neoadjuvant Transarterial Chemoembolization With Doxorubicin in Prostate Cancer Patients Before Radical Prostatectomy(CAPEMCHAR) | terminated | Phase 2 | 12 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Mar 27, 2023 | clinicaltrials |
| NCT02291055 | A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer | terminated | Phase 1 / Phase 2 | 75 | Advaxis, Inc.INDUSTRY | 1 | Mar 20, 2023 | clinicaltrials |
| NCT01709734 | A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer(ARMOR2) | terminated | Phase 2 | 126 | LTN PHARMACEUTICALS, INC.INDUSTRY | 2 | Mar 15, 2023 | clinicaltrials |
| NCT03439033 | Comparison Study of PET/CT or PET/MRI Imaging to Magnetic Resonance Imaging (MRI) Alone in Men With Prostate Cancer | terminated | Phase 2 | 273 | Weill Medical College of Cornell UniversityOTHER | 1 | Mar 13, 2023 | clinicaltrials |
| NCT02721979 | Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance | terminated | Phase 2 | 24 | University of WashingtonOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT02420652 | Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy(PRIMA) | terminated | Phase 2 | 27 | Rutgers, The State University of New JerseyOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT02146833 | SHIP (Selinexor in Hormone Insensitive Prostate Cancer)(SHIP) | terminated | Phase 2 | 20 | Karyopharm Therapeutics IncINDUSTRY | 1 | Jan 26, 2023 | clinicaltrials |
| NCT02393248 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | terminated | Phase 1 / Phase 2 | 201 | Incyte CorporationINDUSTRY | 2 | Jan 6, 2023 | clinicaltrials |
| NCT03933813 | Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients | terminated | Phase 1 / Phase 2 | 9 | University of Wisconsin, MadisonOTHER | 1 | Jan 5, 2023 | clinicaltrials |
| NCT04851834 | NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma | terminated | Phase 1 / Phase 2 | 12 | Xennials Therapeutics Australia Pty LtdINDUSTRY | 1 | Dec 20, 2022 | clinicaltrials |
| NCT02978222 | Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer | terminated | Phase 2 | 120 | Marker Therapeutics, Inc.INDUSTRY | 1 | Dec 15, 2022 | clinicaltrials |
| NCT04928820 | 68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy | terminated | Phase 2 | 22 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Oct 21, 2022 | clinicaltrials |
| NCT03693846 | Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors | terminated | Phase 2 | 11 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT02766478 | Genistein Supplementation to Mitigate Cardiometabolic Dysfunction in Patients Undergoing Androgen Deprivation Therapy for Prostate Cancer(GeniPro) | terminated | Phase 2 | 10 | Emory UniversityOTHER | 1 | Sep 27, 2022 | clinicaltrials |
| NCT00373217 | Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | terminated | Phase 2 | 6 | Craig L Slingluff, JrOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT02203513 | A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer | terminated | Phase 2 | 111 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2022 | clinicaltrials |
| NCT03955471 | Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer(MOONSTONE) | terminated | Phase 2 | 41 | Tesaro, Inc.INDUSTRY | 1 | Sep 10, 2022 | clinicaltrials |
| NCT02601209 | Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma | terminated | Phase 1 / Phase 2 | 151 | National Cancer Institute (NCI)NIH | 1 | Aug 23, 2022 | clinicaltrials |
| NCT03531827 | Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment | terminated | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Jul 12, 2022 | clinicaltrials |
| NCT01681433 | OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone | terminated | Phase 2 | 72 | Costantine AlbanyOTHER | 2 | Jul 11, 2022 | clinicaltrials |
| NCT02499952 | Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors | terminated | Phase 2 | 12 | Nasser Hanna, M.D.OTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT02582749 | Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases | terminated | Phase 2 | 16 | Ajjai Alva, MDOTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT03964337 | Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer(SPARC) | terminated | Phase 2 | 3 | Duke UniversityOTHER | 1 | Jun 29, 2022 | clinicaltrials |
| NCT02837042 | Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma | terminated | Phase 2 | 6 | University of Alabama at BirminghamOTHER | 1 | Jun 21, 2022 | clinicaltrials |
| NCT03100006 | Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin(ORION-01) | terminated | Phase 1 / Phase 2 | 13 | National Cancer Centre, SingaporeOTHER | 1 | Jun 13, 2022 | clinicaltrials |
| NCT02900560 | Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer | terminated | Phase 2 | 34 | Translational Research in OncologyOTHER | 1 | Jun 10, 2022 | clinicaltrials |
| NCT03077698 | An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer | terminated | Phase 2 | 25 | Xenetic Biosciences, Inc.INDUSTRY | 1 | Jun 7, 2022 | clinicaltrials |
| NCT04230954 | Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer | terminated | Phase 2 | 5 | University of South AlabamaOTHER | 1 | Jun 7, 2022 | clinicaltrials |
| NCT03367819 | Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 44 | SanofiINDUSTRY | 5 | May 16, 2022 | clinicaltrials |
| NCT02913131 | Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor Malignancies | terminated | Phase 1 / Phase 2 | 23 | Rahul AggarwalOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT02945813 | SAKK 08/15 - PROMET - Salvage Radiotherapy +/- Metformin for Patients With Prostate Cancer After Prostatectomy | terminated | Phase 2 | 112 | Swiss Cancer InstituteOTHER | 3 | Apr 14, 2022 | clinicaltrials |
| NCT02349386 | Maintaining Suppression of Testosterone With Transdermal Estradiol Gel(MASTERS) | terminated | Phase 2 | 34 | BHR Pharma, LLCINDUSTRY | 1 | Mar 31, 2022 | clinicaltrials |
| NCT04221828 | Trial of NanoPac Focal Therapy for Prostate Cancer | terminated | Phase 2 | 1 | NanOlogy, LLCINDUSTRY | 1 | Mar 29, 2022 | clinicaltrials |
| NCT02362451 | Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer | terminated | Phase 2 | 7 | National Cancer Institute (NCI)NIH | 1 | Mar 18, 2022 | clinicaltrials |
| NCT01650285 | Cabazitaxel and Radiation For Patients With Prostate Cancer | terminated | Phase 2 | 5 | Brown UniversityOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT01650350 | Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer | terminated | Phase 2 | 7 | Brown UniversityOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT03441464 | Feasibility of the LUM Imaging System for Detection of Prostate Cancer | terminated | Phase 1 / Phase 2 | 9 | Lumicell, Inc.INDUSTRY | 1 | Feb 25, 2022 | clinicaltrials |
| NCT00594620 | Soy Derivatives for Control of Hot Flashes in Men on Androgen Deprivation Therapy | terminated | Phase 2 | 11 | University of Kansas Medical CenterOTHER | 1 | Feb 14, 2022 | clinicaltrials |
| NCT03029611 | IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery | terminated | Phase 2 | 11 | University of WashingtonOTHER | 1 | Jan 14, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Aug 1, 2023source: clinicaltrials